33742-70-0

Basic information

• Product Name: 2-Methylamino-3-nitro-6-chloropyridine
• Synonyms: 6-Chloro-2-(N-methylamino)-3-nitropyridine;(6-Chloro-3-nitro-pyridin-2-yl)-Methyl-aMine;Pyridine, 6-chloro-2-(methylamino)-3-nitro-;2-PYRIDINAMINE, 6-CHLORO-N-METHYL-3-NITRO-;2-Methylamino-3-nitro-6-chloropyridine;2-Chloro-6-(methylamino)-5-nitropyridine;6-Chloro-N-methyl-3-nitro-2-pyridinamine;2-METHYLAMINO-3-NITRO-6-CHLORO
• CAS NO: 33742-70-0
• Molecular Formula: C₆H₆ClN₃O₂
• Molecular Weight: 187.58
• Product Categories: Heterocycle-Pyridine series
• Mol File: 33742-70-0.mol
• Article Data: 27

Chemical Properties

• Melting Point: 114 °C
• Boiling Point: 330 °C
• Flash Point: 153 °C
• Appearance: /
• Density: 1.489
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.641
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: -0.67±0.10(Predicted)
• CAS DataBase Reference: 2-Methylamino-3-nitro-6-chloropyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Methylamino-3-nitro-6-chloropyridine(33742-70-0)
• EPA Substance Registry System: 2-Methylamino-3-nitro-6-chloropyridine(33742-70-0)

Safety Data

• Hazardous Substances Data: 33742-70-0(Hazardous Substances Data)

Usage

General Description

2-Methylamino-3-nitro-6-chloropyridine is a chemical compound with the molecular formula C6H6ClN3O2. It is a pyridine derivative with a methylamino group, a nitro group, and a chlorine atom attached to the pyridine ring. 2-Methylamino-3-nitro-6-chloropyridine is mainly used in the synthesis of pharmaceuticals and agrochemicals, particularly as an intermediate in the production of various medications and pesticides. It is also used in research and development for its potential biological and therapeutic activities. However, it is important to handle this compound with care as it can be toxic and harmful if not used properly.

InChI:InChI=1/C6H6ClN3O2/c1-8-6-4(10(11)12)2-3-5(7)9-6/h2-3H,1H3,(H,8,9)

Upstream product

• 5470-18-8 2-Chloro-3-nitropyridine 
• 16013-85-7 2,6-dicholoro-3-nitropyridine 
• 74-89-5 methylamine 

Downstream Products

• 882856-89-5 tert-butyl [(3R,4R)-1-[5-amino-(6-methylamino)-pyridin-2-yl]-4-(2,4,5-trifluorophenyl)piperidin-3-yl]carbamate 
• 172648-61-2 2-methylamino-3-nitro-6-phenylsulfanylpyridine 
• 83472-65-5 5-chloro-3-methyl-3H-imidazo[4,5-b]pyridine 
• 1350440-41-3 4'-[6-{N-methyl-N-(2-(N-methylamino)-3-nitropyridin-6-yl)aminomethyl}-4-methyl-2-propyl-1H-benzimidazol-1-ylmethyl]biphenyl-2-carboxylic acid methyl ester 
• 1276676-58-4 1-(2,2-dimethylpropyl)-3-methyl-5-[(1S,4S)-5-(phenylcarbonyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one 
• 1276676-36-8 1-(2,2-dimethylpropyl)-3-methyl-5-[8-(phenylcarbonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one 
• 1276676-15-3 1-(2,2-dimethylpropyl)-3-methyl-5-[9-(phenylcarbonyl)-2,9-diazaspiro[5.5]undec-2-yl]-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one 
• 1276675-90-1 1-(2,2-dimethylpropyl)-3-methyl-5-(5-phenyl-2,5-diazabicyclo[2.2.2]oct-2-yl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one 
• 1276674-51-1 1-(2,2-dimethylpropyl)-3-methyl-5-{5-[(4-methylphenyl)sulfonyl]-2,5-diazabicyclo[2.2.2]oct-2-yl}-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one 
• 1276674-41-9 1-(2,2-dimethylpropyl)-3-methyl-5-[5-(phenylcarbonyl)-2,5-diazabicyclo[2.2.2]oct-2-yl]-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one 
• 1276674-31-7 N-{1-[1-(2,2-dimethylpropyl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-5-yl]-1,2,3,4-tetrahydroquinolin-3-yl}-4-methylbenzene-sulfonamide 
• 1276674-25-9 5-[3-(benzylamino)-3,4-dihydroquinolin-1(2H)-yl]-1-(2,2-dimethylpropyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one 
• 1276673-81-4 N-{1-[1-(2,2-dimethylpropyl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-5-yl]-1,2,3,4-tetrahydroquinolin-3-yl}benzamide 
• 1365647-53-5 N-{3-[(2-amino-3-methyl-3H-imidazo[4,5-b]pyridin-5-yl)oxy]phenyl}-3-(1-cyano-1-methylethyl)benzamide 

Relevant articles and documents

Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDI

Investigation of a novel amino-aza-benzimidazolone structural class of positive allosteric modulators (PAMs) of metabotropic glutamate receptor 2 (mGluR2) identified [2.2.2]-bicyclic amine 12 as an intriguing lead structure due to its promising physicochemical properties and lipophilic ligand efficiency (LLE). Further optimization led to chiral amide 18, which exhibited strong in vitro activity and attractive pharmacokinetic (PK) properties. Hypothesis-driven target design identified compound 21 as a potent, highly selective, orally bioavailable mGluR2 PAM, which addressed a CYP time-dependent inhibition (TDI) liability of 18, while maintaining excellent drug-like properties with robust in vivo activity in a clinically validated model of antipsychotic potential.

BENZIMIDAZOLE DERIVATIVES AND AZA-BENZIMIDAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF

The present disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The provided compounds may be kinase (e.g., Janus kinase (JAK), e.g., Janus kinase 2 (JAK2)) inhibitors. Also provided are pharmaceutical compositions and kits including the provided compounds. Further provided are methods of using the provided compounds, pharmaceutical compositions, and kits (e.g., for treating a disease (e.g., proliferative disease) in a subject in need thereof).

GLP-1 Receptor Agonists and Uses Thereof

Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.